Pharma Cloud Services Market to Reach $42.9 Billion by 2035, Growing at 14.2% CAGR | Amazon Web Services, Google, Microsoft Azure Among Key Players

The global pharma cloud services market, valued at USD 10.8 billion in 2025, will grow to USD 13.0 billion in 2026 and is forecast to reach USD 42.9 billion by 2035, advancing at a compound annual growth rate (CAGR) of 14.2% over the 2026-2035 period. That trajectory reflects deepening adoption of cloud infrastructure across drug discovery, clinical development, and pharmaceutical manufacturing, as companies race to reduce R&D timelines, cut costs, and meet tightening regulatory data requirements.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/cloud-based-solutions-in-healthcare-market/request-sample.html

MARKET OVERVIEW
Pharma cloud services cover the full spectrum of cloud computing delivery models, including Software as a Service (SaaS), Infrastructure as a Service (IaaS), and Platform as a Service (PaaS), deployed across private, public, and hybrid architectures. The core value proposition is straightforward: pharmaceutical companies gain scalable, HIPAA-compliant access to vast datasets and high-performance computing without building or maintaining equivalent on-premise infrastructure.

The business case is gaining force across every stage of the drug lifecycle. In discovery, cloud platforms provide the computing density needed to screen molecular libraries and identify viable drug candidates faster than traditional hardware allows. During development, cloud-hosted analytics tools manage clinical trial data, monitor adverse events, and support regulatory submissions in real time. In manufacturing, cloud applications improve supply chain visibility, tighten quality control, and help eliminate the batch failures and distribution errors that inflate production costs.

Recent deal activity underscores how seriously the industry is taking this shift. In May 2025, Iktos entered a strategic partnership with Amazon Web Services to make its AI-powered drug design tool, Makya, accessible through AWS infrastructure. That same month, Persist AI closed a USD 12 million Series A funding round to launch a cloud lab platform allowing pharmaceutical companies to develop drug formulations remotely through the company's robotic laboratory facilities. Memorial Sloan Kettering also signed a collaboration with AWS in February 2025 to combine its oncology drug development expertise with AWS cloud and AI capabilities, signaling that the convergence of cloud computing and precision medicine is moving from concept to clinical practice.

KEY GROWTH DRIVERS
Rising Adoption of Decentralized Clinical Trials. The shift from site-centric to virtual trial designs has made secure, scalable cloud infrastructure a functional necessity. Decentralized trials distribute data collection across patients, investigators, sponsors, and CROs in multiple geographies, and cloud platforms provide the shared environment where those stakeholders collaborate, transmit data, and maintain audit trails that satisfy regulatory requirements. The result is faster enrollment, lower site-management costs, and improved patient retention.

AI Integration Across Drug Research and Development. AI-powered analytics require the kind of computing scale that only cloud platforms can deliver economically. Cloud services give pharmaceutical companies access to the infrastructure needed to run machine learning models for virtual drug screening, target identification, lead optimization, and patient stratification in clinical trials. Analysts at Roots Analysis note that integrating AI with cloud computing has the potential to cut drug development costs and timelines by more than 50%, a figure that has accelerated cloud migration across the sector.

Regulatory Pressure on Data Management and Compliance. Agencies including the U.S. Food and Drug Administration are setting increasingly specific expectations for how pharmaceutical companies store, access, and audit research data. Cloud vendors serving the pharma sector invest heavily in GxP certification and validated environments, giving drug developers a faster path to compliance than they could achieve through internal IT buildout.

Demand for Cost-Effective SaaS Applications. Purpose-built SaaS platforms for clinical data management, pharmacovigilance, and commercial operations are displacing legacy systems across pharmaceutical companies of all sizes. These applications lower total cost of ownership by moving software licensing, maintenance, and updates off the buyer's balance sheet, while giving operations teams real-time data access without infrastructure overhead.

MARKET SEGMENTATION
By area of application, drug discovery holds close to 50% of the pharma cloud services market and will grow at a CAGR of 15.2% through 2035. The segment's dominance reflects the computing intensity of early-stage research, where AI-driven compound screening and real-time collaboration across distributed research teams depend on cloud-native infrastructure. Drug development and drug manufacturing round out the application mix, both growing as companies extend cloud adoption beyond discovery into clinical and commercial operations.

By type of cloud, hybrid deployments capture approximately 45% of the market in 2026. That share reflects the practical reality that pharmaceutical companies need the security and access controls of private cloud for sensitive data while drawing on the scalability and cost efficiency of public cloud for batch analytics and collaboration workloads. Public cloud, meanwhile, will grow at the highest CAGR of 15.7% through 2035 as vendor compliance certifications improve and companies grow more comfortable migrating regulated workloads. Among end users, pharmaceutical and life sciences companies account for 65% of current market revenue and will grow at 15.6% annually, driven by accelerated migration away from legacy systems.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/cloud-based-solutions-in-healthcare-market/request-quote.html

REGIONAL INSIGHTS
North America commands approximately 55% of the global pharma cloud services market in 2026, and that position will hold through the forecast period. The region benefits from mature digital infrastructure, the concentrated presence of major cloud providers including Amazon, Microsoft, and Google, and an FDA regulatory environment that actively encourages data modernization. High pharmaceutical R&D spending, particularly in the United States, further cements North American leadership, as large biopharma companies continue to allocate capital toward cloud migration for both clinical and commercial functions.

Asia-Pacific is the fastest-growing region, with a projected CAGR of 17.1% through 2035. Rapid expansion of pharmaceutical R&D capacity in China, India, South Korea, and Japan, combined with government programs to modernize healthcare IT infrastructure, is driving adoption at a pace that outstrips more established markets. Europe holds a meaningful share, supported by established research ecosystems in Germany, the UK, and France, along with GDPR-compliant cloud offerings from major vendors.

COMPETITIVE LANDSCAPE
The report profiles key players including, Alibaba Cloud, Amazon Web Services, Cisco Systems, Clarivate, Cognizant, Dassault Systèmes, DXC Technology, Google, and HCL Technologies, among others. The market features a mix of global hyperscalers, IT services firms, and specialized life sciences software providers competing across technology capability, compliance credentials, and the depth of pharma-specific application portfolios. Partnership activity is a primary competitive mechanism, as cloud platforms seek to embed themselves in pharmaceutical workflows through co-development agreements, data platform integrations, and AI toolchain collaborations. Startups are entering through niche application areas, particularly AI-enabled drug design and clinical data management, putting pressure on incumbents to accelerate product development or acquire capabilities.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/cloud-based-solutions-in-healthcare-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.